By Sriparna Roy (Reuters) -Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant ...

The stock's rise snapped a four-day losing streak.

Bristol Myers Squibb Co.’s treatment for schizophrenia failed in a study designed to expand its use, denting the company’s ...

Bristol Myers Squibb said on Tuesday its drug Cobenfy failed to show a statistically significant difference compared to a ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $58.71, a high ...

Shares of Bristol Myers Squibb tumbled late Tuesday after the company's schizophrenia drug, Cobenfy, failed in a Phase 3 ...

Bristol-Myers Squibb is trading near all-time high dividend and free cash flow yields. Learn why BMY stock is a Buy.

Bristol Myers Squibb's Cobenfy as an adjunctive treatment did not reach the threshold for a statistically significant difference compared to a placebo with an atypical antipsychotic in adults with ...

Bristol-Myers Squibb (BMY) stock is down 11% year-to-date as the company navigates several looming patent cliffs. After a $13 ...

Bristol-Myers Squibb (BMY – Research Report) received a Hold rating and a $55.00 price target from Cantor Fitzgerald analyst Olivia Brayer ...

The new schizophrenia drug didn’t provide additional benefits when given on top of standard-of-care therapy, Bristol Myers ...

The Vatican announced that Pope Francis died from a stroke that was followed by a coma and irreversible cardiocirculatory ...